...
首页> 外文期刊>Intestinal research. >Does Metformin Affect The Incidence of Colonic Polyps and Adenomas in Patients with Type 2 Diabetes Mellitus?
【24h】

Does Metformin Affect The Incidence of Colonic Polyps and Adenomas in Patients with Type 2 Diabetes Mellitus?

机译:二甲双胍是否会影响2型糖尿病患者结肠息肉和腺瘤的发生率?

获取原文
           

摘要

Background/Aims Colorectal cancer (CRC) develops from colonic adenomas. Type 2 diabetes mellitus (DM) is associated with a higher risk of CRC and metformin decreases CRC risk. However, it is not certain if metformin affects the development of colorectal polyps and adenomas. This study aimed to elucidate if metforminaffects the incidence of colonic polyps and adenomas in patients with type 2 DM. Methods Of 12,186 patients with type 2 DM, 3,775 underwent colonoscopy between May 2001 and March 2013. This study enrolled 3,105 of these patients, and divided them in two groups: 912 patients with metformin use and 2,193 patients without metformin use. Patient clinical characteristics, polyp and adenoma detection rate in the two groups were analyzed retrospectively. Results The Colorectal polyp detection rate was lower in the metformin group than in the non-meformin group (39.4% vs. 62.4%, P Conclusions In patients with type 2 DM, metformin reduced the incidence of adenomas that may transform into CRC. Therefore, metformin may be useful for the prevention of CRC in patients with type 2 DM.
机译:背景/目的大肠癌(CRC)从结肠腺瘤发展而来。 2型糖尿病(DM)与更高的CRC风险相关,二甲双胍可降低CRC风险。但是,不确定二甲双胍是否会影响结肠直肠息肉和腺瘤的发展。这项研究旨在阐明二甲双胍是否会影响2型糖尿病患者结肠息肉和腺瘤的发生。方法2001年5月至2013年3月,对12186例2型糖尿病患者中的3775例进行了结肠镜检查。该研究招募了3105例患者,并将其分为两组:912例使用二甲双胍的患者和2193例不使用二甲双胍的患者。回顾性分析两组患者的临床特征,息肉和腺瘤检出率。结果二甲双胍组的结直肠息肉检出率低于非二甲双胍组(39.4%对62.4%,P)结论2型糖尿病患者二甲双胍降低了可能转变为CRC的腺瘤的发生率。二甲双胍可能对2型糖尿病患者的CRC预防很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号